Immunotherapy With Recombinant Alt a 1 Suppresses Allergic Asthma and Influences T Follicular Cells and Regulatory B Cells in Mice
BackgroundAlternaria is a major source of asthma-inducing allergens. Allergen-specific immunotherapy improves the progression of allergic asthma. The current treatment is based on crude Alternaria extracts. Alt a 1 is the predominant allergen in Alternaria. However, the treatment efficacy of recombi...
Guardado en:
Autores principales: | Juan Liu, Jia Yin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aa749f5e1e654be8bce49521ffb60f64 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Purified Native and Recombinant Major <i>Alternaria alternata</i> Allergen (Alt a 1) Induces Allergic Asthma in the Murine Model
por: Ainara Vélez-del-Burgo, et al.
Publicado: (2021) -
Changes in the Sensitization Pattern to <i>Alternaria alternata</i> Allergens in Patients Treated with Alt a 1 Immunotherapy
por: David Rodríguez, et al.
Publicado: (2021) -
ALLERGEN-SPECIFIC IMMUNOTHERAPY: VACCINES FOR ALLERGIC DISEASES
por: A. S. Fedorov, et al.
Publicado: (2015) -
Sublingual immunotherapy increases Treg/Th17 ratio in allergic rhinitis
por: Wang Jiarong, et al.
Publicado: (2021) -
Clinical Relevance and Advantages of Intradermal Test Results in 371 Patients with Allergic Rhinitis, Asthma and/or Otitis Media with Effusion
por: David S. Hurst, et al.
Publicado: (2021)